DarioHealth Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

DarioHealth wird ein jährliches Gewinn- und Umsatzwachstum von 4.6% bzw. 34.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.6% betragen.

Wichtige Informationen

4.6%

Wachstumsrate der Gewinne

7.9%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	26.9%
Wachstumsrate der Einnahmen	34.3%
Zukünftige Eigenkapitalrendite	7.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

May 31

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Feb 16

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

Nov 06

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Oct 07

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Aug 16

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

Aug 15

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 13

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

Oct 05

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Aug 24

DarioHealth Q2 2022 Earnings Preview

Aug 12

DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future

Jul 29

At US$8.95, Is It Time To Put DarioHealth Corp. (NASDAQ:DRIO) On Your Watch List?

Feb 11

DarioHealth: Moving Towards An Inflection Point

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:DRIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	67	-47	-14	-5	1
12/31/2025	46	-50	-9	0	2
12/31/2024	34	-57	-28	-19	2
3/31/2024	19	-49	-39	-39	N/A
12/31/2023	20	-55	-31	-30	N/A
9/30/2023	24	-57	-32	-31	N/A
6/30/2023	27	-57	-33	-33	N/A
3/31/2023	27	-58	-35	-35	N/A
12/31/2022	28	-60	-48	-48	N/A
9/30/2022	27	-65	-56	-55	N/A
6/30/2022	26	-73	-57	-57	N/A
3/31/2022	25	-72	-58	-58	N/A
12/31/2021	21	-68	-51	-50	N/A
9/30/2021	17	-58	-42	-42	N/A
6/30/2021	13	-43	-34	-33	N/A
3/31/2021	10	-32	-24	-24	N/A
12/31/2020	8	-33	-18	-18	N/A
9/30/2020	7	-31	-14	-14	N/A
6/30/2020	7	-26	-13	-13	N/A
3/31/2020	7	-27	-16	-16	N/A
12/31/2019	8	-21	-16	-16	N/A
9/30/2019	7	-19	-16	-16	N/A
6/30/2019	7	-20	-16	-16	N/A
3/31/2019	8	-21	-13	-13	N/A
12/31/2018	7	-18	-12	-11	N/A
9/30/2018	7	-17	-11	-10	N/A
6/30/2018	7	-16	-10	-10	N/A
3/31/2018	6	-14	-11	-10	N/A
12/31/2017	5	-16	N/A	-11	N/A
9/30/2017	4	-16	N/A	-10	N/A
6/30/2017	4	-14	N/A	-10	N/A
3/31/2017	3	-14	N/A	-9	N/A
12/31/2016	3	-12	N/A	-8	N/A
9/30/2016	2	-9	N/A	-9	N/A
6/30/2016	2	-10	N/A	-7	N/A
3/31/2016	1	-8	N/A	-7	N/A
12/31/2015	1	-7	N/A	-6	N/A
9/30/2015	1	-9	N/A	-7	N/A
6/30/2015	0	-14	N/A	-7	N/A
3/31/2015	0	-15	N/A	-8	N/A
12/31/2014	0	-16	N/A	-9	N/A
9/30/2014	N/A	-13	N/A	-8	N/A
6/30/2014	N/A	-10	N/A	-9	N/A
3/31/2014	N/A	-12	N/A	-9	N/A
12/31/2013	N/A	-14	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DRIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DRIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DRIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: DRIODie Einnahmen des Unternehmens (34.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DRIODie Einnahmen des Unternehmens (34.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DRIODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.6%).

DarioHealth Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus revenue estimates decrease by 16%, EPS upgraded

Consensus EPS estimates upgraded to US$1.71 loss, revenue downgraded

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 18%

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

Recent updates

Consensus EPS estimates fall by 11%, revenue upgraded

DarioHealth Corp. Announces Management Changes

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%, EPS upgraded

DarioHealth Corp. to Report Q1, 2024 Results on May 15, 2024

DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Consensus EPS estimates upgraded to US$1.71 loss, revenue downgraded

DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

Consensus EPS estimates fall by 29%

Full year 2023 earnings released: US$2.24 loss per share (vs US$2.54 loss in FY 2022)

DarioHealth Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024

DarioHealth Corp. announced that it has received $22.422 million in funding

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Consensus revenue estimates fall by 18%

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.70 loss in 3Q 2022)

DarioHealth Corp. to Report Q3, 2023 Results on Nov 02, 2023

DarioHealth Corp., Annual General Meeting, Dec 11, 2023

New minor risk - Share price stability

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DarioHealth Corp. to Report Q2, 2023 Results on Aug 10, 2023

DarioHealth Corp. Announces the Presentation of Research at the American Diabetes Association 83(rd) Scientific Sessions

Price target decreased by 13% to US$10.20

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

DarioHealth Corp. announced that it has received funding

DarioHealth Corp. to Report Q1, 2023 Results on May 11, 2023

Consensus EPS estimates upgraded to US$1.75 loss, revenue downgraded

Full year 2022 earnings released: US$2.70 loss per share (vs US$4.75 loss in FY 2021)

DarioHealth Corp. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

DarioHealth Corp. Announces Termination of Dror Bacher, Chief Operating Officer

DarioHealth Corp. Announces Matt Alberico as Senior Vice President of Growth

Independent Director notifies of intention to sell stock

Price target decreased to US$15.02

High number of new and inexperienced directors

DarioHealth Corp. to Report Q3, 2022 Results on Nov 14, 2022

DarioHealth Corp., Annual General Meeting, Dec 07, 2022

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

DarioHealth Corp. Publishes New Clinical Research Linking the Use of Its Biofeedback Device to Reduced Back Pain

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$16.64

DarioHealth Q2 2022 Earnings Preview

DarioHealth Corp. to Report Q2, 2022 Results on Aug 15, 2022

DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future

DarioHealth Corp. announced that it has received $25 million in funding from OrbiMed Advisors LLC

DarioHealth Corp. Announces Demise of Richard Stone, Member of the Board of Directors and Appoints Dennis Matheis to Serve as a Member of the Company's Audit Committee as Well as a Member, and Chair, of the Company's Corporate Governance and Nominating Committee

DarioHealth Corp. Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

DarioHealth Corp. to Report Q1, 2022 Results on May 12, 2022

DarioHealth Corp. Presents New Clinical Research Demonstrating Improved Outcomes for Participants Using Single Integrated Digital Solution to Manage Multiple Chronic Conditions

Price target decreased to US$18.22

High number of new directors

Price target decreased to US$18.22

Consensus forecasts updated

Price target decreased to US$21.22